First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study

OBJECTIVE: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Fc-inactivated anti-β amyloid (Aβ) monoclonal antibody (mAb) GSK933776 in patients with mild Alzheimer’s disease (AD) or mild cognitive impairment (MCI). METHODS: This was a two-part, single blind, placebo-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreasen, Niels, Simeoni, Monica, Ostlund, Henrik, Lisjo, Pia I., Fladby, Tormod, Loercher, Amy E., Byrne, Gerard J., Murray, Frances, Scott-Stevens, Paul T., Wallin, Anders, Zhang, Yinghua Y., Bronge, Lena H., Zetterberg, Henrik, Nordberg, Agneta K., Yeo, Astrid J., Khan, Shahid A., Hilpert, Jan, Mistry, Prafull C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366075/
https://www.ncbi.nlm.nih.gov/pubmed/25789616
http://dx.doi.org/10.1371/journal.pone.0098153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366075/
https://www.ncbi.nlm.nih.gov/pubmed/25789616
http://dx.doi.org/10.1371/journal.pone.0098153

Ejemplares similares